Comparing the current results to its competitors, Natera Inc reported Revenue increase in the 2 quarter 2026 by 37.71 % year on year. The sales growth was above Natera Inc 's competitors' average revenue growth of 12.55 %, achieved in the same quarter.
Natera Inc 's Comment on Competition and Industry Peers
The company operates in a competitive market focused on molecular diagnostic tests in women's health, oncology, and organ transplant rejection. In the non-invasive prenatal testing (NIPT) segment, competitors include BGI; BillionToOne Inc.; Fulgent Genetics; Illumina (through its subsidiary Verinata); Laboratory Corporation of America Holdings (Labcorp); Myriad Genetics, Inc.; Quest Diagnostics Incorporated (Quest); and Revvity Inc. For carrier screening tests, competitors are BillionToOne Inc.; Fulgent Genetics; Labcorp; Myriad Genetics, Inc.; and Quest. In oncology, competitors include BillionToOne Inc.; Caris Life Sciences, Inc.; Exact Sciences Corp.; Guardant Health, Inc.; Personalis, Inc.; Quest; and Tempus Labs, Inc. In organ health, the primary competitor is CareDx.
Strong sales growth of 37.71 % in Overall company contributed to Natera Inc increase in total revenue by 37.71 % Natera Inc improved its market share in this segment, to approximately 11.28 %.
March 4, 2025
In the fast-paced world of genetic testing, Natera, Inc. (NASDAQ: NTRA) has taken significant steps to solidify its position as a leader in the field. The Austin-based company recently announced the issuance of a new patent from the U.S. Patent and Trademark Office that relates to the testing of single nucleotide variants in circulating-tumor DNA (ctDNA). This development not only enhances Natera’s intellectual property portfolio but also underscores its commitment to advancing the capabilities of molecular residual disease (MRD) testing.Natera’s expansion of its patent portfolio is part of a larger strategy to leverage cutting-edge technology in the burgeoning field of personalized medicine. The company...
February 10, 2025
NCCN Strengthens Guidance on ctDNA in Colon, Rectal, and Merkel Cell Carcinoma: Pioneering Advances by Natera In an evolving landscape of cancer diagnostics and treatment, Natera, Inc. (NASDAQ: NTRA), a trailblazer in cell-free DNA and genetic testing, has announced significant strides in the field of oncology. The recent updates by the National Comprehensive Cancer Network (NCCN) which include crucial insights on circulating tumor DNA (ctDNA) as a molecular residual disease (MRD) testing component, underscore the potent role of ctDNA in managing colon cancer, rectal cancer, and Merkel cell carcinoma (MCC). These updates mark a step forward in precision medicine, where Natera s innovations are at the forefro...
December 9, 2024
Natera and MyOme Introduce Integrated Polygenic Risk Score for Breast Cancer, While Financial Stability Reflects Industry LeadershipIn a significant advancement for personalized medicine, Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA and genetic testing, has partnered with MyOme, a pioneer in clinical whole genome analysis and polygenic risk modeling, to launch an integrated polygenic risk score (iPRS) tailored for breast cancer risk assessment. This innovative tool not only estimates individual breast cancer risk over five years and a lifetime but also provides critical insights for patients who have received a negative result from Natera’s Empower hereditary cancer test.The iPRS model represent...
July 28, 2024
for CSIMarket.com : Natera s Signatera Validated for Clinical Utility in Merkel Cell Carcinoma Amid Launch of New Cancer Trial Austin, Texas - Natera Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, has announced promising results from a new multicenter prospective study published in the Journal of Clinical Oncology. The study underscores the clinical utility of Natera s personalized and tumor-informed molecular residual disease (MRD) test, Signatera, in the surveillance of Merkel cell carcinoma (MCC).Merkel cell carcinoma is an aggressive form of skin cancer, characterized by a high mortality rate and a recurrence rate of 40% within five years. Early detection and precise monitor...
July 27, 2024
In the rapidly evolving landscape of oncology, Natera, Inc. (NASDAQ: NTRA) continues to establish itself as a formidable leader in cell-free DNA (cfDNA) and genetic testing. The company s recent developments highlighting the clinical utility of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera represent significant milestones in the fight against aggressive cancers like Merkel cell carcinoma (MCC) and gastroesophageal cancer. Understanding the Stakes: Merkel Cell CarcinomaMerkel cell carcinoma is a rare but aggressive form of skin cancer characterized by a high mortality rate and alarming recurrence rates. With a five-year recurrence risk of approximately 40%, early detect...
May 4, 2024
New Natera Publication Supports Early Detection of Breast Cancer Recurrence with Signatera, According to Study in JCO Precision OncologyNatera, a leading global provider of cell-free DNA and genetic testing, has recently released a publication in JCO Precision Oncology that highlights the effectiveness of their personalized and tumor-informed molecular residual disease (MRD) test, Signatera, in detecting early recurrence in patients with early-stage breast cancer. The study, which analyzed 1,136 plasma samples from 156 early-stage breast cancer patients, reinforces the value of extended surveillance using Signatera.Early-stage breast cancer patients face the constant concern of potential cancer recurrence, e...
April 22, 2024
In the marketplace of medical innovation, peer-reviewed publications play a significant role in displaying the scientific validity and applicability of medical technologies. In the field of genetic analysis and cell-free DNA (cfDNA), Natera, Inc. stands at the vanguard of this genre of advanced medical research. Achieving a significant milestone, Natera, Inc. announced recently that more than 200 peer-reviewed papers touting their underlying science and products have been published.Based in Austin, Texas, and listed on the NASDAQ under the symbol NTRA, Natera is a premier global figure in genetic testing and cell-free DNA analysis. The company s suite of products has been pivotal in testing for various genet...
March 7, 2024
Natera, a leading company in cell-free DNA testing, has announced that it has received commercial insurance coverage for its Prospera Heart and Prospera Kidney tests from one of the largest Blue Cross Blue Shield (BCBS) plans in the United States. This development is significant as it will greatly benefit transplant recipients and providers by allowing them access to advanced non-invasive testing that evaluates the risk of organ transplant rejection.Prospera is a groundbreaking blood test that analyzes donor-derived cell-free DNA (dd-cfDNA) in transplant recipients. By assessing the levels of dd-cfDNA in the bloodstream, Prospera provides crucial information about the potential risk of rejection after an org...
January 25, 2024
Nature Medicine Publishes Two Studies Highlighting Signatera s Clinical Utility in Patients with Gastrointestinal MalignanciesAUSTIN, Texas - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, has recently announced the publication of two new studies in Nature Medicine that evaluate the clinical utility of their personalized and tumor-informed molecular residual disease (MRD) test, Signatera. These studies showcase the potential benefits of Signatera in patients with gastrointestinal malignancies.The first study, called the AMPLIFY-201 trial, focused on assessing the efficacy of the ELI-002 cancer vaccine. This single-arm, phase I study enrolled a total of 25 patients, 20 of whom had panc...
Myriad Genetics Inc's business model revolves around providing molecular diagnostic testing services and developing innovative precision medicine solutions that help identify and personalize treatment options for patients across various medical specialties.
MDxHealth SA is a biotech company that primarily focuses on developing and commercializing molecular diagnostic tests to assist healthcare professionals in making informed treatment decisions for cancer patients. Their business model revolves around providing accurate and actionable diagnostic information to improve patient outcomes and potentially reduce healthcare costs.
Illumina Inc is a leading company in the genomics sector, focusing on next-generation sequencing technologies that enhance genetic analysis. Their business model encompasses a diverse range of products, including sequencing platforms, reagents, and bioinformatics solutions, which together facilitate comprehensive genomic studies for researchers. By integrating these tools, Illumina supports advancements in fields such as oncology, drug discovery, and personalized healthcare, positioning itself at the forefront of genomic innovation.
Sources:
Natera Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Natera Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
